NextCure (NASDAQ:NXTC) Major Shareholder Buys $27,173.58 in Stock

NextCure, Inc. (NASDAQ:NXTC) major shareholder Adar1 Capital Management, Llc bought 5,626 shares of the stock in a transaction that occurred on Friday, October 23rd. The stock was bought at an average cost of $4.83 per share, for a total transaction of $27,173.58. Following the transaction, the insider owned 728,045 shares of the company’s stock, valued at $3,516,457.35. The trade was a 0.78% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Adar1 Capital Management, Llc also recently made the following trade(s):

• On Tuesday, October 27th, Adar1 Capital Management, Llc purchased 3,553 shares of NextCure stock. The shares were bought at an average cost of $5.10 per share, with a total value of $18,120.30.
• On Monday, October 26th, Adar1 Capital Management, Llc purchased 1,672 shares of NextCure stock. The stock was bought at an average price of $5.03 per share, with a total value of $8,410.16.
• On Friday, July 31st, Adar1 Capital Management, Llc purchased 36,303 shares of NextCure stock. The shares were bought at an average cost of $4.94 per share, for a total transaction of $179,336.82.
• On Thursday, July 30th, Adar1 Capital Management, Llc acquired 292,850 shares of NextCure stock. The shares were bought at an average price of $4.93 per share, for a total transaction of $1,443,750.50.
• On Wednesday, July 29th, Adar1 Capital Management, Llc bought 3,410 shares of NextCure stock. The stock was purchased at an average cost of $5.00 per share, with a total value of $17,050.00.

NextCure Trading Up 3.0%

NASDAQ NXTC opened at $6.53 on Friday. The firm’s fifty day moving average price is $6.10 and its two-hundred day moving average price is $7.92. NextCure, Inc. has a 1 year low of $1.55 and a 1 year high of $15.74. The firm has a market capitalization of $23.57 million, a P/E ratio of -0.75 and a beta of 1.33.

NextCure (NASDAQ:NXTC) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($2.80) EPS for the quarter, missing analysts’ consensus estimates of ($1.95) by ($0.85).

Hedge Funds Weigh In On NextCure

A hedge fund recently raised its stake in NextCure stock. Renaissance Technologies LLC lifted its stake in shares of NextCure, Inc. (NASDAQ:NXTC) by 80.0% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 60,534 shares of the company’s stock after purchasing an additional 26,900 shares during the quarter. Renaissance Technologies LLC owned 1.68% of NextCure worth $647,000 as of its most recent SEC filing. Institutional investors and hedge funds own 42.65% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the company. Weiss Ratings cut NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday. Wall Street Zen upgraded NextCure from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Finally, HC Wainwright reissued a “buy” rating on shares of NextCure in a report on Thursday, August 13th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, NextCure presently has a consensus rating of “Hold” and an average target price of $19.00.

About NextCure

NextCure, Inc (NASDAQ: NXTC) is a clinical-stage biotechnology company focused on developing immunomedicines for the treatment of cancer. The company’s research is aimed at identifying and targeting biological mechanisms that suppress the immune system’s ability to recognize and attack tumor cells.

NextCure’s product candidates have included NC318, an antibody designed to target Siglec-6, and NC410, a fusion protein intended to block the LAIR-1 immune-suppressive pathway. These programs have been evaluated in early-stage clinical studies involving patients with advanced solid tumors, with the goal of developing treatments that may restore or enhance anti-tumor immune responses.

Founded in 2015 and headquartered in the United States, NextCure has operated primarily as a research and development company serving the global oncology market through clinical trials and collaborations.